Non-coding RNAs and lipid metabolism

International Journal of Molecular Sciences

Volumn 15, Issue 8, 2014, Pages 13494-13513

  Smolle, Elisabeth ^a   Haybaeck, Johannes ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Dyslipidaemia; Long non coding RNAs; Micro RNAs; Non coding RNAs

Indexed keywords

MICRORNA; UNTRANSLATED RNA;

ADIPOGENESIS; ATHEROSCLEROSIS; DYSLIPIDEMIA; GENETICS; HUMAN; LIPID METABOLISM; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

ADIPOGENESIS; ATHEROSCLEROSIS; DYSLIPIDEMIAS; HUMANS; LIPID METABOLISM; MICRORNAS; OXIDATIVE STRESS; RNA, UNTRANSLATED;

EID: 84905662485     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150813494     Document Type: Review

References (128)

1. Wang, S.; Tran, E.J. Unexpected functions of lncRNAs in gene regulation. Commun. Integr. Biol. 2013,6, doi:10.4161/cib.27610.
2. Ulitsky, I.; Bartel, D.P. LincRNAs: Genomics, evolution, and mechanisms. Cell 2013,154, 26-46.
3. Djebali, S.; Davis, C.A.; Merkel, A.; Dobin, A.; Lassmann, T.; Mortazavi, A.; Tanzer, A.; Lagarde, J.; Lin, W.; Schlesinger, F.;et al. Landscape of transcription in human cells. Nature 2012,489, 101-108.
4. Novikova, I.V.; Hennelly, S.P.; Tung, C.S.; Sanbonmatsu, K.Y. Rise of the RNA machines: Exploring the structure of long non-coding RNAs. J. Mol. Biol. 2013,425, 3731-3746.
5. Kornfeld, J.W.; Bruning, J.C. Regulation ofmetabolism by long, non-coding RNAs. Front. Genet. 2014,5, doi:10.3389/fgene.2014.00057.
6. Penny, G.D.; Kay, G.F.; Sheardown, S.A.; Rastan, S.; Brockdorff, N. Requirement for Xist in X chromosome inactivation. Nature 1996,379, 131-137.
7. Dinger, M.E.; Pang, K.C.; Mercer, T.R.; Mattick, J.S. Differentiating protein-coding and noncoding RNA: Challenges and ambiguities. PLoS Comput. Biol. 2008,4, e1000176.
8. Ernst, C.; Morton, C.C. Identification and function of long non-coding RNA. Front. Cell. Neurosci. 2013,7, doi:10.3389/fncel.2013.00168.
9. Pan, Y.F.; Feng, L.; Zhang, X.Q.; Song, L.J.; Liang, H.X.; Li, Z.Q.; Tao, F.B. Role of long non-coding RNAs in gene regulation and oncogenesis. Chin. Med. J. 2011,124, 2378-2383.
10. Hangauer, M.J.; Vaughn, I.W.; McManus, M.T. Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet. 2013,9, e1003569.
11. Derrien, T.; Johnson, R.; Bussotti, G.; Tanzer, A.; Djebali, S.; Tilgner, H.; Guernec, G.; Martin, D.; Merkel, A.; Knowles, D.G.;et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 2012,22, 1775-1789.
12. Guttman, M.; Amit, I.; Garber, M.; French, C.; Lin, M.F.; Feldser, D.; Huarte, M.; Zuk, O.; Carey, B.W.; Cassady, J.P.;et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009,458, 223-227.
13. Chew, G.L.; Pauli, A.; Rinn, J.L.; Regev, A.; Schier, A.F.; Valen, E. Ribosome profiling reveals resemblance between long non-coding RNAsand 5' leaders of coding RNAs. Development 2013, 140, 2828-2834.
14. Cabili, M.N.; Trapnell, C.; Goff, L.; Koziol, M.; Tazon-Vega, B.; Regev, A.; Rinn, J.L. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011,25, 1915-1927.
15. Guttman, M.; Russell, P.; Ingolia, N.T.; Weissman, J.S.; Lander, E.S. Ribosome profiling provides evidence that large noncoding RNAs do not encode proteins. Cell 2013,154, 240-251.
16. Castelnuovo, M.; Rahman, S.; Guffanti, E.; Infantino, V.; Stutz, F.; Zenklusen, D. Bimodal expression of PHO84 is modulated by early termination of antisense transcription. Nat. Struct. Mol. Biol. 2013,20, 851-858.
17. Camblong, J.; Iglesias, N.; Fickentscher, C.; Dieppois, G.; Stutz, F. Antisense RNA stabilization induces transcriptional gene silencing via histone deacetylation in S. Cerevisiae. Cell 2007,131, 706-717.
18. Martens, J.A.; Laprade, L.; Winston, F. Intergenic transcription is required to repress the saccharomyces cerevisiae SER3 gene. Nature 2004,429, 571-574.
19. Hung, T.; Wang, Y.; Lin, M.F.; Koegel, A.K.; Kotake, Y.; Grant, G.D.; Horlings, H.M.; Shah, N.; Umbricht, C.; Wang, P.;et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat. Genet. 2011,43, 621-629.
20. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004,116, 281-297.
21. Sonkoly, E.; Stahle, M.; Pivarcsi, A. MicroRNAs and immunity: Novel players in the regulation of normal immune function and inflammation. Semin. Cancer Biol. 2008,18, 131-140.
22. Grimson, A.; Farh, K.K.; Johnston, W.K.; Garrett-Engele, P.; Lim, L.P.; Bartel, D.P. MicroRNA targeting specificity inmammals: Determinants beyond seed pairing. Mol. Cell 2007,27, 91-105.
23. Lim, L.P.; Lau, N.C.; Garrett-Engele, P.; Grimson, A.; Schelter, J.M.; Castle, J.; Bartel, D.P.; Linsley, P.S.; Johnson, J.M. Microarray analysisshows that some microRNAs downregulate large numbers of Target mRNAs. Nature 2005,433, 769-773.
24. Lee, Y.; Kim, M.; Han, J.; Yeom, K.H.; Lee, S.; Baek, S.H.; Kim, V.N. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004,23, 4051-4060.
25. Wightman, B.; Ha, I.; Ruvkun, G. Posttranscriptional regulation of the heterochronic gene Lin-14 by Lin-4 mediates temporal pattern formation in C. Elegans. Cell 1993,75, 855-862.
26. O'Connell, R.M.; Rao, D.S.; Chaudhuri, A.A.; Baltimore, D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 2010,10, 111-122.
27. Vickers, K.C.; Rye, K.A.; Tabet, F. MicroRNAs in the onset and development of cardiovascular disease. Clin. Sci. 2014,126, 183-194.
28. Ouimet, M.; Moore, K.J. A big role for small RNAs in HDL homeostasis. J. Lipid Res. 2013,54, 1161-1167.
29. Ladewig, E.; Okamura, K.; Flynt, A.S.; Westholm, J.O.; Lai, E.C. Discovery of hundreds of mirtrons in mouse and human small RNA data. Genome Res. 2012,22, 1634-1645.
30. Lee, Y.; Ahn, C.; Han, J.; Choi, H.; Kim, J.; Yim, J.; Lee, J.; Provost, P.; Radmark, O.; Kim, S.;et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003,425, 415-419.
31. Han, J.; Lee, Y.; Yeom, K.H.; Kim, Y.K.; Jin, H.; Kim, V.N. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004,18, 3016-3027.
32. Lund, E.; Guttinger, S.; Calado, A.; Dahlberg, J.E.; Kutay, U. Nuclear export of microRNA precursors. Science 2004,303, 95-98.
33. Hutvagner, G.; McLachlan, J.; Pasquinelli, A.E.; Balint, E.; Tuschl, T.; Zamore, P.D. A cellular function for the RNA-Interference enzyme dicer in the maturation of the Let-7 small temporal RNA. Science 2001,293, 834-838.
34. Yi, R.; Qin, Y.; Macara, I.G.; Cullen, B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003,17, 3011-3016.
35. Guo, H.; Ingolia, N.T.; Weissman, J.S.; Bartel, D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010,466, 835-840.
36. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009,136, 215-233.
37. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A.;et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008,105, 10513-10518.
38. Fichtlscherer, S.; Zeiher, A.M.; Dimmeler, S. Circulating microRNAs: Biomarkers or mediators of cardiovascular diseases? Arterioscler. Thromb. Vasc. Biol. 2011,31, 2383-2390.
39. Sun, X.; Zhang, M.; Sanagawa, A.; Mori, C.; Ito, S.; Iwaki, S.; Satoh, H.; Fujii, S. Circulating microRNA-126 in patients with coronary artery disease: Correlation with LDL cholesterol. Thromb. J. 2012,10, doi:10.1186/1477-9560-10-16.
40. Vickers, K.C.; Remaley, A.T. Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 2012,23, 91-97.
41. Vickers, K.C.; Palmisano, B.T.; Shoucri, B.M.; Shamburek, R.D.; Remaley, A.T. MicroRNAs are transported in plasma and delivered to recipient Cells by high-density lipoproteins. Nat. Cell Biol. 2011,13, 423-433.
42. Barter, P.; Gotto, A.M.; LaRosa, J.C.; Maroni, J.; Szarek, M.; Grundy, S.M.; Kastelein, J.J.; Bittner, V.; Fruchart, J.C. Treating to new targets investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 2007,357, 1301-1310.
43. Zhao, C.; Dahlman-Wright, K. Liver X receptor in cholesterol metabolism. J. Endocrinol. 2010, 204, 233-240.
44. Min, H.K.; Kapoor, A.; Fuchs, M.; Mirshahi, F.; Zhou, H.; Maher, J.; Kellum, J.; Warnick, R.; Contos, M.J.; Sanyal, A.J. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012, 15, 665-674.
45. Esau, C.; Davis, S.; Murray, S.F.; Yu, X.X.; Pandey, S.K.; Pear, M.; Watts, L.; Booten, S.L.; Graham, M.; McKay, R.;et al. MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006,3, 87-98.
46. Moore, K.J.; Rayner, K.J.; Suarez, Y.; Fernandez-Hernando, C. MicroRNAs and cholesterol metabolism. Trends Endocrinol. Metab. 2010,21, 699-706.
47. Vickers, K.C.; Shoucri, B.M.; Levin, M.G.; Wu, H.; Pearson, D.S.; Osei-Hwedieh, D.; Collins, F.S.; Remaley, A.T.; Sethupathy, P. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology 2013,57, 533-542.
48. Kida, K.; Nakajima, M.; Mohri, T.; Oda, Y.; Takagi, S.; Fukami, T.; Yokoi, T. PPARalpha is regulated by miR-21 and miR-27b in human liver. Pharm. Res. 2011,28, 2467-2476.
49. Zheng, L.; Lv, G.C.; Sheng, J.; Yang, Y.D. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-α expression, a novel mechanism for the pathogenesis of NAFLD. J. Gastroenterol. Hepatol. 2010,25, 156-163.
50. Rayner, K.J.; Sheedy, F.J.; Esau, C.C.; Hussain, F.N.; Temel, R.E.; Parathath, S.; van Gils, J.M.; Rayner, A.J.; Chang, A.N.; Suarez, Y.;et al. Antagonism of miR-33 inmice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Investig. 2011,121, 2921-2931.
51. Rayner, K.J.; Suarez, Y.; Davalos, A.; Parathath, S.; Fitzgerald, M.L.; Tamehiro, N.; Fisher, E.A.; Moore, K.J.; Fernandez-Hernando, C. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010,328, 1570-1573.
52. Marquart, T.J.; Allen, R.M.; Ory, D.S.; Baldan, A. MiR-33 links SREBP-2 induction to repression of sterol transporters. Proc. Natl. Acad. Sci. USA 2010,107, 12228-12232.
53. Gerin, I.; Clerbaux, L.A.; Haumont, O.; Lanthier, N.; Das, A.K.; Burant, C.F.; Leclercq, I.A.; MacDougald, O.A.; Bommer, G.T. Expression ofmiR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J. Biol. Chem. 2010,285, 33652-33661.
54. Horie, T.; Ono, K.; Horiguchi, M.; Nishi, H.; Nakamura, T.; Nagao, K.; Kinoshita, M.; Kuwabara, Y.; Marusawa, H.; Iwanaga, Y.;et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc. Natl. Acad. Sci. USA 2010,107, 17321-17326.
55. Najafi-Shoushtari, S.H.; Kristo, F.; Li, Y.; Shioda, T.; Cohen, D.E.; Gerszten, R.E.; Naar, A.M. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010,328, 1566-1569.
56. Espenshade, P.J.; Hughes, A.L. Regulation of sterol synthesis in eukaryotes. Annu. Rev. Genet. 2007,41, 401-427.
57. Allen, R.M.; Marquart, T.J.; Albert, C.J.; Suchy, F.J.; Wang, D.Q.; Ananthanarayanan, M.; Ford, D.A.; Baldan, A. MiR-33 controls the expression of biliary transporters, and mediates statin-and diet-induced hepatotoxicity. EMBO Mol. Med. 2012,4, 882-895.
58. Davalos, A.; Goedeke, L.; Smibert, P.; Ramirez, C.M.; Warrier, N.P.; Andreo, U.; Cirera-Salinas, D.; Rayner, K.; Suresh, U.; Pastor-Pareja, J.C.;et al. MiR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc. Natl. Acad. Sci. USA 2011,108, 9232-9237.
59. Rayner, K.J.; Esau, C.C.; Hussain, F.N.; McDaniel, A.L.; Marshall, S.M.; van Gils, J.M.; Ray, T.D.; Sheedy, F.J.; Goedeke, L.; Liu, X.;et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011,478, 404-407.
60. Elmen, J.; Lindow, M.; Schutz, S.; Lawrence, M.; Petri, A.; Obad, S.; Lindholm, M.; Hedtjarn, M.; Hansen, H.F.; Berger, U.;et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008,452, 896-899.
61. Elmen, J.; Lindow, M.; Silahtaroglu, A.; Bak, M.; Christensen, M.; Lind-Thomsen, A.; Hedtjarn, M.; Hansen, J.B.; Hansen, H.F.; Straarup, E.M.;et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008,36, 1153-1162.
62. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivowith "antagomirs". Nature 2005,438, 685-689.
63. Hsu, S.H.; Wang, B.; Kota, J.; Yu, J.; Costinean, S.; Kutay, H.; Yu, L.; Bai, S.; La Perle, K.; Chivukula, R.R.;et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Investig. 2012,122, 2871-2883.
64. Tsai, W.C.; Hsu, S.D.; Hsu, C.S.; Lai, T.C.; Chen, S.J.; Shen, R.; Huang, Y.; Chen, H.C.; Lee, C.H.; Tsai, T.F.;et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Investig. 2012,122, 2884-2897.
65. Ramirez, C.M.; Rotllan, N.; Vlassov, A.V.; Davalos, A.; Li, M.; Goedeke, L.; Aranda, J.F.; Cirera-Salinas, D.; Araldi, E.; Salerno, A.;et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ. Res. 2013,112, 1592-1601.
66. Ramirez, C.M.; Davalos, A.; Goedeke, L.; Salerno, A.G.; Warrier, N.; Cirera-Salinas, D.; Suarez, Y.; Fernandez-Hernando, C. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler. Thromb. Vasc. Biol. 2011,31, 2707-2714.
67. Kim, J.; Yoon, H.; Ramirez, C.M.; Lee, S.M.; Hoe, H.S.; Fernandez-Hernando, C.; Kim, J. MiR-106b impairs cholesterol efflux and increases Aβlevels by repressing ABCA1 expression. Exp. Neurol. 2012,235, 476-483.
68. Sun, D.; Zhang, J.; Xie, J.; Wei, W.; Chen, M.; Zhao, X. MiR-26 controls LXR-dependent cholesterol efflux by targeting ABCA1 and ARL7. FEBS Lett. 2012,586, 1472-1479.
69. Zhong, D.; Huang, G.; Zhang, Y.; Zeng, Y.; Xu, Z.; Zhao, Y.; He, X.; He, F. MicroRNA-1 and microRNA-206 suppress LXR α-Induced Lipogenesis in Hepatocytes. Cell Signal. 2013,25, 1429-1437.
70. Zhong, D.; Zhang, Y.; Zeng, Y.J.; Gao, M.; Wu, G.Z.; Hu, C.J.; Huang, G.; He, F.T. MicroRNA-613 represses lipogenesis inHepG2 cells by downregulating LXR α. Lipids Health Dis. 2013,12, doi:10.1186/1476-511X-12-32.
71. Yang, K.; He, Y.S.; Wang, X.Q.; Lu, L.; Chen, Q.J.; Liu, J.; Sun, Z.; Shen, W.F. MiR-146a inhibits oxidized low-density lipoprotein-inducedlipid accumulation and inflammatory response via targeting toll-like receptor 4. FEBS Lett. 2011,585, 854-860.
72. Chen, T.; Huang, Z.; Wang, L.; Wang, Y.; Wu, F.; Meng, S.; Wang, C. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc. Res. 2009,83, 131-139.
73. Huang, R.S.; Hu, G.Q.; Lin, B.; Lin, Z.Y.; Sun, C.C. MicroRNA-155 silencing enhances inflammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages. J. Investig. Med. 2010,58, 961-967.
74. Hu, Z.; Shen, W.J.; Kraemer, F.B.; Azhar, S. MicroRNAs 125a and 455 repress lipoprotein-supported steroidogenesis by targeting scavenger receptor class B type I in steroidogenic cells. Mol. Cell. Biol. 2012,32, 5035-5045.
75. Wang, L.; Jia, X.J.; Jiang, H.J.; Du, Y.; Yang, F.; Si, S.Y.; Hong, B. MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition. Mol. Cell. Biol. 2013,33, 1956-1964.
76. Yin, H.; Hu, M.; Zhang, R.; Shen, Z.; Flatow, L.; You, M. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J. Biol. Chem. 2012,287, 9817-9826.
77. Wang, F.; Ma, Y.L.; Zhang, P.; Yang, J.J.; Chen, H.Q.; Liu, Z.H.; Peng, J.Y.; Zhou, Y.K.; Qin, H.L. A genetic variant in microRNA-196a2 isassociated with increased cancer risk: a meta-analysis. Mol. Biol. Rep. 2012,39, 269-275.
78. Kapeller, J.; Houghton, L.A.; Monnikes, H.; Walstab, J.; Moller, D.; Bonisch, H.; Burwinkel, B.; Autschbach, F.; Funke, B.; Lasitschka, F.;et al. First evidence for an association of a functional variant in the microRNA-510 targetsite of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum. Mol. Genet. 2008,17, 2967-2977.
79. Park, Y.S.; Jeon, Y.J.; Lee, B.E.; Kim, T.G.; Choi, J.U.; Kim, D.S.; Kim, N.K. Association of the miR-146aC>G, miR-196a2C>T, and miR-499A>G polymorphisms with moyamoya disease in the Korean population. Neurosci. Lett. 2012,521, 71-75.
80. Arnold, M.; Ellwanger, D.C.; Hartsperger, M.L.; Pfeufer, A.; Stumpflen, V. Cis-acting polymorphisms affect complex traits through modifications of microRNA regulation pathways. PLoS One 2012,7, e36694.
81. Fan, C.; Chen, C.; Wu, D. The association between common genetic variant of microRNA-499 and cancer susceptibility: a meta-analysis. Mol. Biol. Rep. 2013,40, 3389-3394.
82. Richardson, K.; Nettleton, J.A.; Rotllan, N.; Tanaka, T.; Smith, C.E.; Lai, C.Q.; Parnell, L.D.; Lee, Y.C.; Lahti, J.; Lemaitre, R.N.;et al. Gain-of-function lipoprotein lipase variant rs13702 modulates lipid traits through disruption of a microRNA-410 seed site. Am. J. Hum. Genet. 2013, 92, 5-14.
83. Zhu, H.; Fan, G.C. Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am. J. Cardiovasc. Dis. 2011,1, 138-149.
84. Besler, C.; Luscher, T.F.; Landmesser, U. Molecular mechanisms of vascular effects of high-density lipoprotein: Alterations in cardiovascular disease. EMBO Mol. Med. 2012,4, 251-268.
85. Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352, 1685-1695.
86. Pober, J.S.; Sessa, W.C. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 2007,7, 803-815.
87. Harris, T.A.; Yamakuchi, M.; Ferlito, M.; Mendell, J.T.; Lowenstein, C.J. MicroRNA-126 regulates endothelial expression of vascular celladhesion molecule 1. Proc. Natl. Acad. Sci. USA 2008,105, 1516-1521.
88. Hu, Y.W.; Hu, Y.R.; Zhao, J.Y.; Li, S.F.; Ma, X.; Wu, S.G.; Lu, J.B.; Qiu, Y.R.; Sha, Y.H.; Wang, Y.C.;et al. An agomir of miR-144-3p accelerates plaque formation through impairing reverse cholesterol transport and promoting pro-inflammatory cytokine production. PLoS One 2014,9, e94997.
89. Finkel, T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol. 2003,15, 247-254.
90. Irani, K. Oxidant signaling in vascular cell growth, death, and survival: A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ. Res. 2000,87, 179-183.
91. Madamanchi, N.R.; Vendrov, A.; Runge, M.S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005,25, 29-38.
92. Napoli, C.; de Nigris, F.; Palinski, W. Multiple role of reactive oxygen species in the arterial wall. J. Cell. Biochem. 2001,82, 674-682.
93. Magenta, A.; Greco, S.; Gaetano, C.; Martelli, F. Oxidative stress and microRNAs in vascular diseases. Int. J. Mol. Sci. 2013,14, 17319-17346.
94. Shen, X.; Zheng, S.; Thongboonkerd, V.; Xu, M.; Pierce, W.M., Jr.; Klein, J.B.; Epstein, P.N. Cardiac mitochondrial damage and biogenesis in a chronic model of Type 1 diabetes. Am. J. Physiol. Endocrinol. Metab. 2004,287, E896-E905.
95. Villeneuve, L.M.; Reddy, M.A.; Lanting, L.L.; Wang, M.; Meng, L.; Natarajan, R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc. Natl. Acad. Sci. USA 2008,105, 9047-9052.
96. Alcendor, R.R.; Gao, S.; Zhai, P.; Zablocki, D.; Holle, E.; Yu, X.; Tian, B.; Wagner, T.; Vatner, S.F.; Sadoshima, J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 2007,100, 1512-1521.
97. Menghini, R.; Casagrande, V.; Cardellini, M.; Martelli, E.; Terrinoni, A.; Amati, F.; Vasa-Nicotera, M.; Ippoliti, A.; Novelli, G.; Melino, G.;et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 2009,120, 1524-1532.
98. Helgadottir, A.; Thorleifsson, G.; Manolescu, A.; Gretarsdottir, S.; Blondal, T.; Jonasdottir, A.; Jonasdottir, A.; Sigurdsson, A.; Baker, A.; Palsson, A.;et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007,316, 1491-1493.
99. McPherson, R.; Pertsemlidis, A.; Kavaslar, N.; Stewart, A.; Roberts, R.; Cox, D.R.; Hinds, D.A.; Pennacchio, L.A.; Tybjaerg-Hansen, A.; Folsom, A.R.;et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007,316, 1488-1491.
100. Yap, K.L.; Li, S.; Munoz-Cabello, A.M.; Raguz, S.; Zeng, L.; Mujtaba, S.; Gil, J.; Walsh, M.J.; Zhou, M.M. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol. Cell 2010,38, 662-674.
101. Samani, N.J.; Erdmann, J.; Hall, A.S.; Hengstenberg, C.; Mangino, M.; Mayer, B.; Dixon, R.J.; Meitinger, T.; Braund, P.; Wichmann, H.E.;et al. Genomewide association analysis of coronary artery disease. N. Engl. J. Med. 2007,357, 443-453.
102. Folkersen, L.; Kyriakou, T.; Goel, A.; Peden, J.; Malarstig, A.; Paulsson-Berne, G.; Hamsten, A.; Hugh, W.; Franco-Cereceda, A.; Gabrielsen, A.;et al. Relationship between CAD risk genotype in the chromosome 9p21 locus and gene expression. Identification of eight new ANRIL splice variants. PLoS One 2009,4, e7677.
103. Holdt, L.M.; Beutner, F.; Scholz, M.; Gielen, S.; Gabel, G.; Bergert, H.; Schuler, G.; Thiery, J.; Teupser, D. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler. Thromb. Vasc. Biol. 2010,30, 620-627.
104. Holdt, L.M.; Teupser, D. Recent studies of the human chromosome 9p21 locus, which is associated with atherosclerosis in human populations. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 196-206.
105. Cunnington, M.S.; Santibanez Koref, M.; Mayosi, B.M.; Burn, J.; Keavney, B. Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet. 2010,6, e1000899.
106. Jarinova, O.; Stewart, A.F.; Roberts, R.; Wells, G.; Lau, P.; Naing, T.; Buerki, C.; McLean, B.W.; Cook, R.C.; Parker, J.S.;et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler. Thromb. Vasc. Biol. 2009,29, 1671-1677.
107. Liu, Y.; Sanoff, H.K.; Cho, H.; Burd, C.E.; Torrice, C.; Mohlke, K.L.; Ibrahim, J.G.; Thomas, N.E.; Sharpless, N.E. INK4/ARF transcript expression is associatedwith chromosome 9p21 variants linked to atherosclerosis. PLoS One 2009,4, e5027.
108. Holdt, L.M.; Hoffmann, S.; Sass, K.; Langenberger, D.; Scholz, M.; Krohn, K.; Finstermeier, K.; Stahringer, A.; Wilfert, W.; Beutner, F.;et al. Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS Genet. 2013,9, e1003588.
109. Ellis, B.C.; Graham, L.D.; Molloy, P.L. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim. Biophys. Acta 2014,1843, 372-386.
110. Ding, G.L.; Wang, F.F.; Shu, J.; Tian, S.; Jiang, Y.; Zhang, D.; Wang, N.; Luo, Q.; Zhang, Y.; Jin, F.;et al. Transgenerational glucose intolerance with Igf2/H19 epigenetic alterations in mouse islet induced by intrauterine hyperglycemia. Diabetes 2012,61, 1133-1142.
111. Metzger, B.E.; Buchanan, T.A.; Coustan, D.R.; de Leiva, A.; Dunger, D.B.; Hadden, D.R.; Hod, M.; Kitzmiller, J.L.; Kjos, S.L.; Oats, J.N.;et al. Summary and recommendations of the fifth international workshop-conference on gestational diabetes mellitus. Diabetes Care 2007,30 (Suppl. 2), S251-S260.
112. Bateson, P.; Barker, D.; Clutton-Brock, T.; Deb, D.; D'Udine, B.; Foley, R.A.; Gluckman, P.; Godfrey, K.; Kirkwood, T.; Lahr, M.M.;et al. Developmental plasticity and human health. Nature 2004,430, 419-421.
113. Moran, I.; Akerman, I.; van de Bunt, M.; Xie, R.; Benazra, M.; Nammo, T.; Arnes, L.; Nakic, N.; Garcia-Hurtado, J.; Rodriguez-Segui, S.;et al. Human β cell transcriptome analysis uncovers lncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. Cell Metab. 2012,16, 435-448.
114. Ku, G.M.; Kim, H.; Vaughn, I.W.; Hangauer, M.J.; Myung Oh, C.; German, M.S.; McManus, M.T. Research resource: RNA-Seq reveals unique features of the pancreatic β-cell transcriptome. Mol. Endocrinol. 2012,26, 1783-1792.
115. Saltiel, A.R.; Kahn, C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001,414, 799-806.
116. Gregor, M.F.; Hotamisligil, G.S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011,29, 415-445.
117. Glass, C.K.; Olefsky, J.M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012,15, 635-645.
118. Xu, B.; Gerin, I.; Miao, H.; Vu-Phan, D.; Johnson, C.N.; Xu, R.; Chen, X.W.; Cawthorn, W.P.; MacDougald, O.A.; Koenig, R.J. Multiple roles for the non-coding RNA SRA in regulation of adipogenesis and insulin sensitivity. PLoS One 2010,5, e14199.
119. Sun, L.; Goff, L.A.; Trapnell, C.; Alexander, R.; Lo, K.A.; Hacisuleyman, E.; Sauvageau, M.; Tazon-Vega, B.; Kelley, D.R.; Hendrickson, D.G.;et al. Long noncoding RNAs regulate adipogenesis. Proc. Natl. Acad. Sci. USA 2013,110, 3387-3392.
120. Callegari, E.; Elamin, B.K.; Giannone, F.; Milazzo, M.; Altavilla, G.; Fornari, F.; Giacomelli, L.; D'Abundo, L.; Ferracin, M.; Bassi, C.;et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 2012,56, 1025-1033.
121. Bai, S.; Nasser, M.W.; Wang, B.; Hsu, S.H.; Datta, J.; Kutay, H.; Yadav, A.; Nuovo, G.; Kumar, P.; Ghoshal, K. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 2009,284, 32015-32027.
122. Tomimaru, Y.; Eguchi, H.; Nagano, H.; Wada, H.; Tomokuni, A.; Kobayashi, S.; Marubashi, S.; Takeda, Y.; Tanemura, M.; Umeshita, K.;et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br. J. Cancer 2010,103, 1617-1626.
123. Duan, Y.; Hu, L.; Liu, B.; Yu, B.; Li, J.; Yan, M.; Yu, Y.; Li, C.; Su, L.; Zhu, Z.;et al. Tumor suppressor miR-24 restrains gastric cancerprogression by downregulating RegIV. Mol. Cancer 2014,13, doi:10.1186/1476-4598-13-127.
124. Rayner, K.J.; Fernandez-Hernando, C.; Moore, K.J. MicroRNAs regulating lipid metabolism in atherogenesis. Thromb. Haemost. 2012,107, 642-647.
125. Wang, Z. The Guideline of the design and validation of MiRNA mimics. Methods Mol. Biol. 2011,676, 211-223.
126. Jamaluddin, M.S.; Weakley, S.M.; Zhang, L.; Kougias, P.; Lin, P.H.; Yao, Q.; Chen, C. MiRNAs: Roles and clinical applications in vascular disease. Expert Rev. Mol. Diagn. 2011,11, 79-89.
127. Stenvang, J.; Petri, A.; Lindow, M.; Obad, S.; Kauppinen, S. Inhibitionof microRNA function by antimiR oligonucleotides. Silence 2012,3, doi:10.1186/1758-907X-3-1.
128. Ebert, M.S.; Neilson, J.R.; Sharp, P.A. MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007,4, 721-726.